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Abstract 
Background: The platelet–lymphocyte ratio (PLR) and neutrophil–lymphocyte ratio (NLR) have been reported as 
prognostic factors in various cancers, but their roles in metastatic renal cell cancer (mRCC) remain unclear. We inves‑
tigated the significance of PLR and NLR, along with that of established prognostic factors, in mRCC patients receiving 
first‑line tyrosine kinase inhibitors (TKI).
Methods: Data obtained from 63 mRCC patients who received first‑line TKI between 2007 and 2013 were evaluated 
retrospectively. The association of PLR, NLR, and established prognostic factors with progression‑free survival (PFS) 
and overall survival (OS) was analyzed using the Kaplan–Meier method. The influence of independent prognostic fac‑
tors on survival was determined using multivariable Cox regression analysis.
Results: High NLR (>3.6) and PLR (>150) were related to shorter PFS (p = 0.001) and OS (p = 0.001). The presence of 
brain metastases [hazard ratio (HR) 4.94, 95% CI 1.75–13.9; p = 0.002] and high PLR (>150, HR 13.1, 95% CI 5.14–33.2; 
p = 0.001) were independently associated with PFS, and Eastern Cooperative Oncology Group Performance status ≥2 
(HR 3.60, 95% CI 1.39–9.31; p = 0.008), lymph node metastasis (HR 2.76, 95% CI 1.11–6.86; p = 0.029), brain metastasis 
(HR 9.39, 95% CI 2.74–32.1; p = 0.001), and high PLR (>150, HR 16.1, 95% CI 4.41–58.4; p = 0.001) with OS.
Conclusions: High PLR was associated with shorter survival of mRCC patients receiving first‑line TKI. The PLR may be 
an effective independent prognostic factor in this setting.
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Background
Renal cell carcinoma (RCC) is the most common type 
of kidney cancer in adults. It accounts for approximately 
3% of adult malignancies and 90–95% of neoplasms aris-
ing from the kidney. Patients with RCC progress to a 
metastatic stage in approximately 33% of cases (Gunduz 
et  al. 2015). The management of patients with meta-
static RCC (mRCC) is complicated by the lack of proven 
effectiveness of accessible therapies. Recently, tyrosine 
kinase inhibitors (TKI) such as sunitinib, sorafenib, or 
pazopanib have become a common choice for first-line 
targeted treatment of mRCC (Noronha et al. 2016). Com-
mon metastatic sites include the lung, liver, bones, brain, 
and adrenal gland, while many case reports describe 
the capacity of RCC to metastasize almost anywhere in 
the body. More than one organ system is often affected 
by the metastatic process. Metastases may be found at 
the time of diagnosis or at any point after nephrectomy 
(Thyavihally et  al. 2005). About 20–50% of patients will 
eventually develop a metastatic disease after nephrec-
tomy. A shorter time interval between nephrectomy 
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and the development of metastases is associated with a 
poor prognosis. Also, the presence of biological signs of 
inflammation, shorter time interval between diagnos-
ing a renal tumor and developing metastases (<1  year), 
elevated neutrophil counts, liver metastases, bone metas-
tases, patient performance status (PS), the number of 
metastatic sites, alkaline phosphatase and hemoglobin 
levels are predictive factors of survival outcome (Heng 
et al. 2009). The crucial role of microenvironment inflam-
mation in the development and progression of malig-
nancies by influencing the proliferation and survival of 
tumor cells, promoting angiogenesis and metastasis, and 
reducing responses to anti-cancer agents has been recog-
nized (Gunduz et al. 2015; de Vivar Chevez et al. 2014). 
Recently, several biomarkers and hematological indi-
ces representative of systemic inflammatory responses, 
including the neutrophil–lymphocyte ratio (NLR), the 
platelet–lymphocyte ratio (PLR), and the combination 
of the C-reactive protein (CRP) and albumin known as 
the Glasgow prognostic score (GPS) were introduced as 
prognostic factors in various cancers. For example, the 
NLR and PLR have been suggested as prognostic indi-
cators for lung, colorectal, breast, gastric and pancre-
atic cancer, as well as urinary cancers such as RCC, and 
urothelial carcinoma (Feng et  al. 2014; Raungkaewma-
nee et al. 2012; Hu et al. 2015; Song et al. 2016; Nakano 
et al. 2014). Templeton et al. (2014a, b) investigated the 
prognostic role of NLR and PLR in solid tumors. In their 
meta-analyses, both high NLR and PLR were associated 
with adverse overall survival (OS). Moreover, the effect of 
high PLR on OS was greater for metastatic disease than 
for early stage disease (Templeton et al. 2014b). However, 
Keskin et  al. (2014) showed that only preoperative high 
NLR was associated with mortality in renal cell carci-
noma. Thus, the aim of this study was to investigate the 
relationship of NLR, PLR, and previously known prog-




The data of 63 patients who had received first-line TKI 
for mRCC between 2007 and 2013 were reviewed retro-
spectively. Patients with histologically confirmed mRCC 
(all clear cell histology) who had received first-line suni-
tinib or pazopanib according to the standardly approved 
schedule and dosage were eligible for this study. Suni-
tinib was administered at a dose of 50  mg per day for 
4  weeks, followed by a 2-week rest. Pazopanib was 
administered at a dose of 800 mg per day, continuously 
during 4  weeks. Both TKIs were prescribed strictly as 
monotherapy, in either standard everyday clinical prac-
tice or as a part of a clinical trial. Dose reduction was 
performed in a case of toxicity, according to standard 
recommendations for the two agents. Before treatment, 
the patient’s age, sex, clinical symptoms, medical history, 
and performance status were evaluated by physicians. 
Blood samples were collected for serum chemistry and 
hematological testing. Chest, abdominal and pelvic com-
puted tomography, and positron emission tomography–
computed tomography were also performed. Responses 
were evaluated every 8–12 weeks after the treatment ini-
tiation by chest and abdominopelvic computed tomog-
raphy or by the same tests that were used to stage initial 
tumors. TKI therapy was given until objective disease 
progression per Response Criteria in Solid Tumors v. 
1.1 criteria (Eisenhauer et al. 2009). PFS was defined as 
the period of time between the initial administration of 
a treatment and the first detection of tumor progression 
based on radiological criteria or death. OS was calcu-
lated from the start of treatment to the date of any cause 
of death.
Assessment of Eastern Cooperative Oncology Group 
Performance status (ECOG‑PS), NLR and PLR
ECOG-PS was assessed at the time of diagnosis. Data 
on pretreatment blood cell counts were extracted in a 
retrospective fashion from the medical records. White 
blood cell and differential counts were assessed just prior 
to administration of TKIs. The NLR was defined as the 
absolute neutrophil count divided by the absolute lym-
phocyte count, and was categorized into two groups 
(≤3.6 and >3.6). Similarly, PLR was defined as the abso-
lute platelet count divided by the absolute lymphocyte 
count, and was also categorized into two groups (≤150 
and >150). The cut-off values were evaluated using the 
receiver operating characteristic (ROC) curve.
Statistical analysis
Statistical analysis was conducted using IBM SPSS soft-
ware package version 21.0 (Statistical Package for Social 
Sciences, IBM, Armonk, NY) and MedCalc software ver-
sion 15 (MedCalc Software bvba, Ostend, Belgium). The 
PFS and OS were calculated using the Kaplan–Meier 
method. Multivariable analyses using the Cox regression 
proportional hazard model were performed to evalu-
ate the prognostic significance of all parameters on PFS 
and OS. ROC curves were plotted to verify the accuracy 
of the obtained significance of NLR and PLR on overall 




The clinical characteristics of 63 patients who received 
first-line TKI for mRCC are summarized in Table 1.
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The group consisted of 52 men and 11 women, with a 
median age of 63 [interquartile range (IQR), 56.0–70.5] 
years. The median follow up period was 17.5  months 
(IQR 9.2–28.4  months). Thirty-five (55.6%) patients had 
undergone previous nephrectomy, 36 (57.1%) patients 
had ECOG PS < 2, and 40 (64%) patients had developed 
metastases within 1  year. Nineteen patients had bone 
metastases, 39 had lung metastases, 6 had liver metasta-
ses, 25 had lymph node metastases, 5 had brain metas-
tases and 31 patients presented with multiple metastatic 
sites. Hemoglobin level of <12 was found in 25 (39.7%) 
patients, corrected calcium level of <10 in 57 (90.5%) 
patients, 48 (76.2%) patients had tumor progression, and 
29 (46.0%) patients died. In addition, most patients had 
favorable (n = 19, 30.2%) or intermediate (n = 41, 65.1%) 
risk as determined by Memorial Sloan Kettering Cancer 
Center criteria (Motzer et al. 1999).
Values of NLR  >  3.6 and PLR  >  150 were obtained in 
29 (46.0%) and 26 (41.3%) patients, respectively. Suni-
tinib was administered to 40 patients and pazopanib 
to 23 patients. Four types of response to TKIs were 
defined: complete response (CR), partial response (PR), 
stable disease (SD) and progressive disease (PD), which 
were detected in 3 (4.8%), 12 (19.0%), 35 (55.6%) and 13 
(20.9%) cases, respectively. Finally, 31 patients received 
second line treatments using everolimus after TKI failure.
ROC curves for NLR and PLR
The areas under the ROC curves for NLR and PLR 
were 0.72 (p = 0.002) and 0.75 (p = 0.001), respectively 
(Fig.  1). However, the difference between the NLR and 
PLR values was not significant (p = 0.620).
Table 1 Patient demographics
Patient no., n 63
Age, median (IQR) 63.1 (56.0–70.5)
Median follow up, months (IQR) 17.5 (9.2–28.4)
Sex, n (%)
 Male 52 (82.5)
 Female 11 (17.5)
ECOG PS, n (%)
 0–1 36 (57.1)
 ≥2 27 (42.9)
Disease free interval, n (%)
 <1 year 40 (63.5)
 ≥1 year 23 (36.5)
Lung metastasis, n (%)
 Yes 39 (61.9)
 No 24 (38.1)
Liver metastasis, n (%)
 Yes 6 (9.5)
 No 57 (90.5)
Lymph node metastasis, n (%)
 Yes 25 (39.7)
 No 38 (60.3)
Bone metastasis, n (%)
 Yes 19 (30.2)
 No 44 (69.8)
Brain metastasis, n (%)
 Yes 5 (7.9)
 No 58 (92.1)
Metastasis at other site, n (%)
 Yes 13 (20.6)
 No 50 (79.4)
Number of metastatic sites, n (%)
 1 37 (54.4)
 ≥2 31 (45.6)
Previous nephrectomy, n (%)
 Yes 35 (55.6)
 No 28 (44.4)
TKI regimen, n (%)
 Sunitinib 40 (63.5)
 Pazopanib 23 (36.5)
Response to TKIs, n (%)
 CR 3 (4.8)
 PR 12 (19.0)
 SD 35 (55.6)
 PD 13 (20.6)
Neutrophil–lymphocyte ratio, n (%)
 ≤3.6 34 (54.0)
 >3.6 29 (46.0)
Platelet–lymphocyte ratio, n (%)
 ≤150 37 (58.7)
 >150 26 (41.3)
IQR Interquartile range, ECOG PS Eastern cooperative oncology group 
performance status, TKI Tyrosine kinase inhibitor, CR complete response, PR 
partial response, SD stable disease, PD progressive disease, MSKCC Memorial 
Sloan Kettering Cancer Center
Table 1 continued
Patient no., n 63
Hemoglobin, n (%)
 <12 (g/dL) 25 (39.7)
 ≥12 (g/dL) 38 (60.3)
Corrected calcium, n (%)
 <10 (mg/dL) 57 (90.5)
 ≥10 (mg/dL) 6 (9.5)
MSKCC risk
 Favorable 19 (30.2)
 Intermediate 41 (65.1)
 Poor 3 (4.8)
 Progression 48 (76.2)
 Death 29 (46.0)
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The effect of clinical variables and prognostic factors 
on PFS and OS
The median PFS and OS were 10.3 months (95% CI 8.7–
11.9) and 31.9  months (95% CI 14.2–49.5), respectively. 
The results of the Kaplan–Meier analysis of the effect of 
clinical parameters on PFS and OS are shown in Table 2. 
Shorter PFS was associated with an ECOG score ≥2, 
the presence of brain metastases, ≥2 metastatic sites, 
NLR > 3.6 and PLR > 150 (Table 2, all p < 0.05 values). 
Multivariable analysis showed that brain metastases (HR 
4.94, 95% CI 1.75–13.9; p =  0.001) and PLR  >  150 (HR 
13.1, 95% CI 5.14–33.2; p  =  0.001) were independent 
prognostic factors of PFS (Table 3).
Meanwhile, ECOG PS  ≥  2, lymph node metastasis, 
bone metastasis, brain metastasis, number of meta-
static sites ≥2, NLR  >  3.6, and PLR  >  150 were related 
to shorter OS (Table 2, all p < 0.05). Also, ECOG PS ≥ 2 
(HR 3.60, 95% CI 1.39–9.31; p  =  0.008), lymph node 
metastasis (HR 2.76, 95% CI 1.11–6.86; p = 0.029), brain 
metastasis (HR 9.39, 95% CI 2.74–32.1; p =  0.001), and 
PLR  >  150 (HR 16.1, 95% CI 4.4–58.4; p =  0.001) were 
independent prognostic factors of OS (Table 3).
Discussion
Guidelines for the treatment of mRCC are rapidly evolv-
ing to incorporate the recently approved molecular-
targeted therapies. Many mRCC patients have a poor 
prognosis, and TKIs have extremely changed their pros-
pects. Prognostic factors can help clinicians determine 
the most appropriate use of TKIs by selecting the patients 
most likely to benefit from them (Noronha et  al. 2016). 
Although numerous studies have attempted to determine 
which clinical factors might be predictors of PFS and OS, 
the results were inconsistent (Heng et  al. 2009; Raung-
kaewmanee et  al. 2012). In this study, we analyzed data 
obtained from 63 mRCC patients receiving first-line TKI 
with the aim of performing prognostic evaluations and 
promoting optimal surveillance strategies. Many stud-
ies have proved that a poor ECOG PS remains one of the 
most significant prognostic factors for various malignan-
cies, such as GI cancer, lung cancer, ovarian cancer and 
mRCC (Zimmermann et al. 2010). Patients with a worse 
ECOG PS and limited functional capacity tend to toler-
ate cancer treatments with more difficulty. These patients 
have less favorable outcomes than patients with a better 
PS. This has been further strengthened by similar con-
clusions obtained from this study. However, one of the 
challenges when using PS as a prognostic measure is that 
it is subjective and may not be reproducible (Laird et al. 
2013), as it is difficult to determine it accurately in the 
busy clinical setting, relying heavily on patient-reported 
information. In 1999, the Memorial Sloan-Kettering 
Cancer Center (MSKCC) reported for the first time that 
hemoglobin level lower than the normal limit, corrected 
calcium level higher than the normal limit, Karnofsky 
performance status lower than 80% and less than 1 year 
interval from diagnosis to treatment were independent 
predictors of short survival (Motzer et  al. 1999; Cetin 
et  al. 2014). This study defined pretreatment clinical 
features that were prognostic of survival in previously 
untreated mRCC patients who subsequently received 
cytokine therapy, such as IFN-α. Heng et al. (2009) also 
reported that lower hemoglobin level and higher serum 
corrected calcium, poor PS, and less than 1 year interval 
from initial diagnosis to initiation of therapy were inde-
pendent predictive factors of poor survival. However, our 
study showed that hemoglobin and calcium levels were 
not significantly associated with the prognosis outcome 
of mRCC patients. Vickers et al. (2013) suggested that the 
number of brain metastases is also a prognostic factor 
of OS. Our study also found that the presence of brain 
metastases is associated with poor OS, while no signifi-
cant correlation with PFS was observed. Kroeger et  al. 
(2015) reported that the presence of lymph node metas-
tases below the diaphragm is associated with poor sur-
vival in mRCC patients treated with targeted therapies. 
Our results are consistent with theirs concerning OS, 
but not PFS. The prognostic role of previous nephrec-
tomy has recently been reported in patients with mRCC 
treated with target therapy (Choueiri et al. 2011; de Groot 
et  al. 2016). Our results suggest that previous nephrec-
tomy was not a significant prognostic factor for mRCC 
patients. All these differences may be due to the small 
number of analyzed mRCC patients and the characteris-
tics of the study group, thus, further studies are needed.
Fig. 1 Receiver operator characteristic curves for the neutrophil‑lym‑
phocyte ratio (NLR) and the platelet–lymphocyte ratio (PLR). For NLR: 
area under the curve = 0.72, p = 0.002, sensitivity = 72.4%, specific‑
ity = 76.4%, accuracy = 74.6%. For PLR: area under the curve = 0.75, 
p = 0.001, sensitivity = 68.9%, specificity = 79.4%, accuracy = 73.0%
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Since Lu et al. (2006) suggested that tumors might form 
as a consequence of chronic inflammation, many studies 
have confirmed that inflammation is crucial for the devel-
opment and progression of cancer. Therefore, inflamma-
tion markers have been regarded as significant for tumor 
progression and as risk factors for tumor recurrence. It 
has been recently suggested that systemic inflammation-
based scores such as GPS (including albumin and CRP 
values), NLR, and PLR might be significant predictors 
of OS and PFS of cancer patients (de Vivar Chevez et al. 
2014; Feng et al. 2014; Raungkaewmanee et al. 2012; Hu 
et  al. 2015; Song et  al. 2016; Nakano et  al. 2014; Tem-
pleton et  al. 2014a, b; Keskin et  al. 2014). Over the last 
decade, it has become clear that these parameters are 
consistently associated with poor outcome, regardless of 
the tumor stage. Several studies suggested that inflam-
mation is the key component of the tumor microenviron-
ment, and that it has a significant role in carcinogenesis 
and disease progression (Balkwill and Mantovani 2012). 
Recent studies have tried to shed new light on molecular 
and cellular pathways linking inflammation and cancer 
(Porta et al. 2009). Despite the fact that RCC is an immu-
nogenic tumor, there is little evidence that immune cells 
and inflammatory pathways can enhance the tumor’s 
growth and immune escape. However, recent studies 
are beginning to uncover the mechanisms of immune 
escape in RCC, and the role of inflammatory immune 
cells and cytokines is this process (Gunduz et al. 2015; de 
Vivar Chevez et  al. 2014). Tumor-associated neutrophils 
Table 2 Results of  the Kaplan–Meier analysis of  progres-
sion free and overall survival
PFS, months 
(95% CI)




 <64 years 10.3 (8.4–12.2) 0.714 31.9 (11.7–52.1) 0.751
 ≥64 years 10.4 (6.7–14.1) 27.1 (5.3–48.8)
Sex
 Male 10.6 (7.5–13.6) 0.245 31.9 (12.2–51.6) 0.936
 Female 10.1 (5.8–14.2) 25.8 (8.2–43.4)
ECOG PS
 0–1 15.1 (9.2–20.9) 0.001 63.5 (30.8–96.2) 0.001
 ≥2 8.2 (3.4–12.9) 15.1 (10.7–19.5)
Disease free interval
 <1 year 9.2 (5.1–13.3) 0.063 22.0 (0–50.5) 0.131
 ≥1 year 13.2 (9.2–17.2) 41.1 (16.1–65.9)
Lung metastasis
 Yes 6.9 (2.0–11.7) 0.139 27.1 (18.4–35.7) 0.722
 No 13.2 (6.7–19.7) 37.2 (12.7–61.7)
Liver metastasis
 Yes 4.3 (0.0–11.1) 0.680 14.4 (0–49.1) 0.388
 No 10.4 (8.9–12.0) 31.9 (15.8–48.0)
Lymph node metastasis
 Yes 10.3 (7.6–13.0) 0.180 14.4 (9.1–19.7) 0.037
 No 10.4 (7.9–12.9) 40.3 (28.4–52.1)
Bone metastasis
 Yes 10.1 (6.6–13.4) 0.309 18.2 (13.3–23.1) 0.021
 No 10.6 (8.8–12.3) 40.3 (20.2–60.3)
Brain metastasis
 Yes 3.2 (2.1–4.3) 0.001 5.9 (0.1–11.7) 0.012
 No 10.6 (9.0–12.1) 37.2 (17.1–57.3)
Metastasis at other site
 Yes 9.1 (5.8–12.5) 0.620 27.1 (10.7–43.4) 0.384
 No 10.4 (8.4–12.4) 63.5 (6.2–120.8)
Number of metastatic site
 1 13.2 (8.7–17.7) 0.001 40.3 (24.7–55.8) 0.007
 ≥2 5.0 (0.4–9.6) 13.7 (9.3–18.1)
Previous nephrectomy
 Yes 10.5 (6.0–15.1) 0.522 37.2 (19.1–55.3) 0.113
 No 10.3 (7.1–13.5) 18.2 (6.6–29.7)
TKI regimen
 Sunitinib 10.1 (7.6–12.5) 0.664 37.2 (15.9–58.5) 0.786
 Pazopanib 10.6 (10.1–11.1) 25.8 (10.2–41.3)
Neutrophil–lymphocyte ratio
 ≤3.6 16.3 (10.4–22.2) 0.001 63.5 (37.4–89.6) 0.001
 >3.6 5.0 (0.7–9.3) 17.0 (12.4–21.6)
Platelet–lymphocyte ratio
 ≤150 18.1 (6.2–29.9) 0.001 50.5 (28.5–72.4) 0.001
 >150 4.4 (3.5–5.3) 13.7 (7.8–19.6)
Hemoglobin
 <12 (g/dL) 7.2 (0.3–13.9) 0.237 25.8 (8.3–43.2) 0.252








 <10 (mg/dL) 10.3 (8.7–11.9) 0.652 31.9 (14.4–49.4) 0.206
 ≥10 (mg/dL) Not reached Not reached
Table 3 Results of  the multivariable analysis of  variables 
affecting progression free and overall survival





HR p value HR p value




Brain metastasis 4.94 (1.75–13.9) 0.002 9.39 (2.74–32.1) 0.001
Platelet–lympho‑
cyte ratio (>150)
13.1 (5.14–33.2) 0.001 16.1 (4.4–58.4) 0.001
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(TANs) have a significant role in the malignant setting, as 
they may act as potent antitumor effector cells. However, 
increasing clinical evidence shows that TANs correlate 
with poor prognosis. As the tumor microenvironment 
controls neutrophil recruitment, TANs help tumor pro-
gression (Uribe-Querol and Rosales 2015). Reduction of 
lymphocyte infiltration in cancer-adjacent tissues tends 
to lead to the proliferation and metastasis of tumor cells 
(Whiteside 2014). Platelets can also lead to a higher level 
of cancer-related coagulation (Falanga et  al. 2013). It is 
possible that active systemic inflammation induces a poor 
local immune response to a tumor, leading to lymph node 
spread and metastasis. Therefore, the ratios of platelets, 
neutrophils, and lymphocytes might be important prog-
nostic factors in various cancers. Raungkaewmanee et al. 
(2012) studied the predictive value of PLR and NLR on 
the outcome of epithelial ovarian cancer patients. They 
reported that higher pretreatment PLR led to shorter PFS 
and OS, and that PLR was a better prognostic predic-
tor of survival than NLR. However, Chrom et  al. (2016) 
showed that only NLR  ≥  4 was significantly associated 
with shorter survival, while PLR ≥ 200 tended to associ-
ate with poor survival. Moreover, recent study revealed 
that high NLR at baseline and high NLR after targeted 
therapy was associated with shorter PFS and OS in mRCC 
(Templeton et al. 2016). However, this study investigated 
the effect of NLR on PFS and OS without other prognos-
tic factors. Although our study included relative small 
patients, we evaluated the effect of PLR on PFS and OS in 
mRCC in addition to NLR and other prognostic factors. 
The data obtained in this study are not entirely in accord-
ance with available literature data. We found that ECOG 
PS ≥ 2, brain metastases, multiple metastases, high NLR 
(>3.6), and high PLR (>150) were predictors of shorter 
PFS and poor OS when performing a Kaplan–Meier anal-
ysis. However, only the presence of brain metastases and 
a high PLR (>150) were found to be significant prognos-
tic factors in terms of PFS and OS when performing the 
multivariable analysis. Our study has several limitations. 
First, it was a retrospective uncontrolled study regard-
ing a single center’s experience with a relatively uncom-
mon disease, thus, the number of analyzed patients was 
quite small. Second, the follow-up period might not have 
been long enough, so a further randomized clinical study 
involving more mRCC patients is needed. Third, the NLR 
and PLR cutoff values have not been previously estab-
lished and were selected from the ROC curves. Fourth, 
we did not assess underlying disorders and other variables 
(e.g., diabetes mellitus, hypertension, body mass index, 
smoking, diet, nutrition) of the patients. Finally, our find-
ings were expressed in terms of PFS and OS, rather than 
cancer specific survival. However, an inflammation-
based prognostic score is a simple, convenient, and easily 
determined parameter that clinicians can use for assess-
ing the prognosis of mRCC patients.
Conclusions
Our results suggest that a high PLR (>150) and brain 
metastases were associated with shorter PFS and poor 
OS in patients with mRCC. In addition, higher PS (≥2) 
and lymph node metastases were associated with shorter 
OS. As PLR can be determined by readily available and 
inexpensive tests, it might serve as an ideal biomarker for 
predicting the survival of patients with mRCC. Patients 
with high PLR might require a more appropriate treat-
ment than first-line TKI such as immunotherapy using 
PD-1/PD-L1 inhibitors, but a larger prospective and 
multi-institutional study is needed in order to confirm 
these data.
Abbreviations
PLR: platelet–lymphocyte ratio; NLR: neutrophil–lymphocyte ratio; mRCC: 
metastatic renal cell cancer; TKI: tyrosine kinase inhibitors; CRP: C‑reactive 
protein; PFS: progression‑free survival; OS: overall survival; HR: hazard ratio; PS: 
performance status.
Authors’ contributions
ECH participated in the design of the study, performed the statistical analysis 
and draft the manuscript. JEH participated in the design of the study and 
performed the statistical analysis. TJP, YHC, HSC, SHJ, JWK, SHH and YHH 
collected the clinical data. WKB, SIJ and DDK made critical revision of the 
manuscript for important intellectual content. TJP and ECH conceived of the 
study, and approved the final manuscript. All authors read and approved the 
final manuscript.
Author details
1 Department of Urology, Chonnam National University Medical School, 
42 Jebongro, Donggu, Gwangju 501‑757, Republic of Korea. 2 Department 
of Hemato‑Oncology, Chonnam National University Medical School, Gwangju, 
Republic of Korea. 3 Department of Radiology, Chonnam National University 
Medical School, Gwangju, Republic of Korea. 4 Department of Hepato‑Pancre‑
ato‑Biliary Surgery, Chonnam National University Medical School, Gwangju, 




The authors declare that they have no competing interests.
Ethical approval and consent to participate
All procedures performed in studies involving human participants were in 
accordance with the ethical standards of the institutional research committee. 
The institutional ethics committee approved this study, and Informed consent 
was waived by the board.
Received: 25 June 2016   Accepted: 21 October 2016
References
Balkwill FR, Mantovani A (2012) Cancer‑related inflammation: common 
themes and therapeutic opportunities. Semin Cancer Biol 22:33–40
Cetin B, Afsar B, Deger SM, Gonul II, Gumusay O, Ozet A, Benekli M, Coskun U, 
Buyukberber S (2014) Association between hemoglobin, calcium, and 
Page 7 of 7Park et al. SpringerPlus  (2016) 5:1889 
lactate dehydrogenase variability and mortality among metastatic renal 
cell carcinoma. Int Urol Nephrol 46:1081–1087
Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDer‑
mott DF, Rini BI, Heng DY (2011) The impact of cytoreductive nephrec‑
tomy on survival of patients with metastatic renal cell carcinoma receiv‑
ing vascular endothelial growth factor targeted therapy. J Urol 185:60–66
Chrom P, Stec R, Semeniuk‑Wojtas A, Bodnar L, Spencer NJ, Szczylik C (2016) 
Fuhrman grade and neutrophil‑to‑lymphocyte ratio influence on 
survival in patients with metastatic renal cell carcinoma treated with 
first‑line tyrosine kinase inhibitors. Clin Genitourin Cancer. doi:10.1016/j.
clgc.2016.02.005
de Groot S, Redekop WK, Sleijfer S, Oosterwijk E, Bex A, Kiemeney LA, Uyl‑de 
Groot CA (2016) Survival in patients with primary metastatic renal cell 
carcinoma treated with sunitinib with or without previous cytoreduc‑
tive nephrectomy: results from a population‑based registry. Urology. 
doi:10.1016/j.urology.2016.04.042
de Vivar Chevez AR, Finke J, Bukowski R (2014) The role of inflammation in 
kidney cancer. Adv Exp Med Biol 816:197–234
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, 
Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan 
R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Falanga A, Marchetti M, Vignoli A (2013) Coagulation and cancer: biological 
and clinical aspects. J Thromb Haemost 11:223–233
Feng JF, Huang Y, Chen QX (2014) Preoperative platelet lymphocyte ratio (PLR) 
is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in 
patients with esophageal squamous cell carcinoma. World J Surg Oncol 
12:58
Gunduz S, Mutlu H, Tural D, Yildiz Ö, Uysal M, Coskun HS, Bozcuk H (2015) 
Platelet to lymphocyte ratio as a new prognostic for patients with meta‑
static renal cell cancer. Asia Pac J Clin Oncol 11:288–292
Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether 
JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, 
McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK 
(2009) Prognostic factors for overall survival in patients with metastatic 
renal cell carcinoma treated with vascular endothelial growth factor‑
targeted agents: results from a large, multicenter study. J Clin Oncol 
27:5794–5799
Hu K, Lou L, Ye J, Zhang S (2015) Prognostic role of the neutrophil–lymphocyte 
ratio in renal cell carcinoma: a meta‑analysis. BMJ Open 5:e006404
Keskin S, Keskin Z, Taskapu HH, Kalkan H, Kaynar M, Poyraz N, Toy H (2014) 
Prognostic value of preoperative neutrophil‑to‑lymphocyte and platelet‑
to‑lymphocyte ratios, and multiphasic renal tomography findings in 
histological subtypes of renal cell carcinoma. BMC Urol 14:95
Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, 
Bjarnason GA, Templeton A, Knox J, Bernstein E, Smoragiewicz M, Lee J, 
Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, 
Heng DY (2015) Characterizing the impact of lymph node metastases on 
the survival outcome for metastatic renal cell carcinoma patients treated 
with targeted therapies. Eur Urol 68:506–515
Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, Klepstad P 
(2013) Prognostic factors in patients with advanced cancer: a comparison 
of clinicopathological factors and the development of an inflammation‑
based prognostic system. Clin Cancer Res 19:5456–5464
Lu H, Ouyang W, Huang C (2006) Inflammation, a key event in cancer develop‑
ment. Mol Cancer Res 4:221–233
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) 
Survival and prognostic stratification of 670 patients with advanced renal 
cell carcinoma. J Clin Oncol 17:2530–2540
Nakano K, Hosoda M, Yamamoto M, Yamashita H (2014) Prognostic signifi‑
cance of pre‑treatment neutrophil: lymphocyte ratio in Japanese patients 
with breast cancer. Anticancer Res 34:3819–3824
Noronha V, Joshi A, Bakshi G, Tongaonkar H, Prabhash K (2016) Current evi‑
dence and the evolving role of sunitinib in the management of renal cell 
carcinoma. Indian J Cancer 53:102–108
Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A, Sica A (2009) 
Cellular and molecular pathways linking inflammation and cancer. Immu‑
nobiology 214:761–777
Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, 
Thavaramara T (2012) Platelet to lymphocyte ratio as a prognostic factor 
for epithelial ovarian cancer. J Gynecol Oncol 23:265–273
Song X, Zhang GM, Ma XC, Luo L, Li B, Chai DY, Sun LJ (2016) Comparison 
of preoperative neutrophil‑lymphocyte, lymphocyte‑monocyte, and 
platelet‑lymphocyte ratios in patients with upper urinary tract urothelial 
carcinoma undergoing radical nephroureterectomy. Onco Targets Ther 
9:1399–1407
Templeton AJ, McNamara MG, Šeruga B, Vera‑Badillo FE, Aneja P, Ocaña A, 
Leibowitz‑Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014a) 
Prognostic role of neutrophil‑to‑lymphocyte ratio in solid tumors: a 
systematic review and meta‑analysis. J Natl Cancer Inst 106:dju124
Templeton AJ, Ace O, McNamara MG, Al‑Mubarak M, Vera‑Badillo FE, Her‑
manns T, Seruga B, Ocaña A, Tannock IF, Amir E (2014b) Prognostic role 
of platelet to lymphocyte ratio in solid tumors: a systematic review and 
meta‑analysis. Cancer Epidemiol Biomarkers Prev 23:1204–1212
Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, Broom R, Fay AP, 
Rini B, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C, 
Kanesvaran R, Alimohamed N, Hermanns T, Wells JC, Amir E, Choueiri TK, 
Heng DY (2016) Change in neutrophil‑to‑lymphocyte ratio in response to 
targeted therapy for metastatic renal cell carcinoma as a prognosticator 
and biomarker of efficacy. Eur Urol 70:358–364
Thyavihally YB, Mahantshetty U, Chamarajanagar RS, Raibhattanavar SG, 
Tongaonkar HB (2005) Management of renal cell carcinoma with solitary 
metastasis. World J Surg Oncol 3:48
Uribe‑Querol E, Rosales C (2015) Neutrophils in cancer: two sides of the same 
coin. J Immunol Res. doi:10.1155/jir.2015.983698
Vickers MM, Al‑Harbi H, Choueiri TK, Kollmannsberger C, North S, MacKenzie 
M, Knox JJ, Rini BI, Heng DY (2013) Prognostic factors of survival for 
patients with metastatic renal cell carcinoma with brain metastases 
treated with targeted therapy: results from the international metastatic 
renal cell carcinoma database consortium. Clin Genitourin Cancer 
11:311–315
Whiteside TL (2014) Tumor‑infiltrating lymphocytes and their role in solid 
tumor progression. In: Klink M (ed) Interaction of immune and cancer 
cells. Springer, Vienna, pp 111–121
Zimmermann C, Burman D, Bandukwala S, Seccareccia D, Kaya E, Bryson J, 
Rodin G, Lo C (2010) Nurse and physician inter‑rater agreement of three 
performance status measures in palliative care outpatients. Support Care 
Cancer 18:609–616
